The BIRC6 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line. Engineered through CRISPR/Cas9-mediated gene disruption of the BIRC6 locus, the cells comprise a heterogeneous pool harboring targeted loss-of-function modifications. This polyclonal format avoids clonal selection biases, enabling direct assessment of gene perturbation in a genetically diverse population. These cells are a powerful tool for dissecting BIRC6 roles in apoptosis, autophagy, and therapeutic resistance.
The parental A-549 cell line was originally established from the lung adenocarcinoma of a 58-year-old Caucasian male. As an epithelial cell line derived from a human lung adenocarcinoma, A-549 cells are widely employed as a model for studying non-small cell lung cancer (NSCLC) biology, including tumor cell signaling and drug response. Their adherent growth and well-characterized mutation landscape make them particularly suitable for generating knockout derivatives and conducting comparative functional studies.
BIRC6 encodes BRUCE/Apollon, a 528 kDa IAP family anti-apoptotic E3 ubiquitin ligase. It directly binds and ubiquitinates pro-apoptotic factors SMAC/DIABLO, HtrA2/Omi, and initiator caspase-9, targeting them for proteasomal degradation and inhibiting the mitochondrial apoptotic cascade. By suppressing executioner caspases-3 and -7, BIRC6 prevents cytochrome c/Apaf-1-mediated apoptosome activation. Additionally, BIRC6 regulates autophagy through ubiquitin-conjugating activity. Upstream, p53 transcriptionally activates pro-apoptotic genes and promotes SMAC release, counteracting BIRC6 function. Thus, BIRC6 intersects apoptosis and autophagy pathways, and its disruption sensitizes cells to mitochondrial outer membrane permeabilization and caspase-dependent death.
In A-549 lung adenocarcinoma cells, BIRC6 knockout provides a relevant paradigm for investigating apoptosis evasion mechanisms prevalent in NSCLC. A-549 cells rely on IAP-mediated survival, making them responsive to BIRC6 disruption. Loss of BIRC6 disrupts ubiquitin-dependent turnover of SMAC and HtrA2, enhancing sensitivity to intrinsic apoptotic stimuli such as chemotherapeutics. The polyclonal knockout population mirrors tumor genetic heterogeneity, increasing translational relevance for studying drug resistance and cell survival.
The BIRC6 Knockout A-549 Polyclonal Cells are suitable for apoptosis research, including investigation of mitochondrial pathway activation and caspase processing. They enable screening for pro-apoptotic compounds and autophagy modulation studies in lung cancer. Users can employ western blotting for cleaved caspase-3/PARP, Annexin V/PI flow cytometry, and viability assays to quantify apoptosis. Co-immunoprecipitation assesses disrupted BIRC6-SMAC interactions, while colony formation and xenograft assays provide functional readouts. This knockout model facilitates elucidation of BIRC6 biology and discovery of therapies targeting apoptosis resistance in lung adenocarcinoma. For further details, please contact Ascent Research.
